Trials Sponsors Conditions Drugs Pricing

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Outcome Measures

Primary Outcomes (4)

Eosinophil level
Blood eosinophil level at baseline and changes over time
3 years
Exhaled nitric oxide level
Exhaled nitric oxide level at baseline and changes over time
3 years
Immunoglobulin E level
Blood immunoglobulin E level at baseline and changes over time
3 years
Lung function: FEV1
FEV1 at baseline and changes over time
3 years

Secondary Outcomes (4)

Lung Function: FVC
3 years
Lung function: FEV1/FVC ratio
3 years
Exacerbations
3 years
Mortality
3 years

Study Arms (1)

COPD patients

Prospective COPD subjects will be recruited from the hospital

Eligibility Criteria

Age40 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients will be recruited from the out-patient general medical and respiratory clinics of the Prince of Wales Hospital. Also, patients admitted for acute exacerbation of COPD will be recruited upon discharge at the Prince of Wales Hospital.

You may qualify if:

\) Patient with COPD with compatible history and lung function assessment according to Global Obstructive Lung Disease (GOLD): Patient has chronic respiratory symptoms (dyspnoea, cough, sputum production and exacerbations due to abnormalities of the airway (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow limitation. Lung function assessment with forced spirometry demonstrated the presence of a post-bronchodilator FEV1/FVC \<70%.14 2) Patient with age ≥40 years

Sponsors & Collaborators

Chinese University of Hong Kong
Otherlead

Study Sites (1)

The Chinese University of Hong Kong

Hong Kong, Hong Kong

RECRUITING

David SC Hui, MDCONTACT852 35053133 dschui@cuhk.edu.hk

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

David SC Hui, MD
Chinese University of Hong Kong
STUDY CHAIR

Central Study Contacts

Fanny WS Ko, MD

CONTACT

852 35033133 fannyko@cuhk.edu.hk

David SC Hui, MD

CONTACT

852 35053133

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Honorary Clinical professor

Study Record Dates

First Submitted

April 20, 2025

First Posted

May 1, 2025

Study Start

May 2, 2025

Actual (reported)

Primary Completion

April 24, 2029

Estimated

A Study on COPD Phenotypes, Endotypes and Treatable Traits

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (1)

COPD patients

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (4)

Secondary Outcomes (4)

Study Arms (1)

COPD patients

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations